US 2019/0290749 A1 · IMMUNE MODULATOR AND VACCINE COMPOSITION CONTAINING THE SAME

Abstract

The present invention relates to an immune modulator having a novel structure, and an immunologic adjuvant composition containing the same and, more specifically, to an modulator, which is a lipopolysaccharide (LPS) analog having reduced toxicity, and a use thereof. The immune modulator of the present invention exhibits immune enhancement effects by having excellent innate immunity and ability to induce an adaptive immune response to a specific pathogen, and is very safe by having low toxicity. In addition, a vaccine containing the immune modulator of the present invention contains both an immune modulator and an alum, thereby improving immune enhancement effects compared with when using only the immune modulator.

Claims12

Dependent claims

An immune modulator represented by the following Formula 1:

wherein Glc is glucose, GlcN is glucosamine, HEP is heptose, KDO is 2-keto-3-deoxy-octonate, GlcNAc is N-acetylglucosamine, and A to F are positions to which phosphates can be bonded.

Dependencies are inferred from the claim text.

Facts

Application

16/345,699Filed 30 Oct 2017

Priority

KR 10-2016-014270331 Oct 2016

Published

26 Sep 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification19 codes

A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens
C08B 37/0063
Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence;…
A61K 31/739
Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers,…:…
A61K 39/00
Medicinal preparations containing antigens or antibodies

Immune modulator and vaccine composition containing the same

Life of this patent

Immune modulator and vaccine composition containing the same

Life of this patent

Abstract

Claims12